Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 3/20 | 0.40 |
| ▸ | ATM | Q13315 | 13/20 | 0.38 |
| ▸ | PIK3C3 | Q8NEB9 | 8/20 | 0.38 |
| ▸ | ATR | Q13535 | 2/20 | 0.38 |
| ▸ | PRKDC | P78527 | 1/20 | 0.37 |
| ▸ | PIM1 | P11309 | 1/20 | 0.35 |
| ▸ | KMO | O15229 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3495289 | 0.89 | TMEM97 (0.39) | KIF11ATMPIK3C3ATR | |
| SCHEMBL3492277 | 0.87 | CA1 (0.43) | KIF11ATMPIK3C3ATRPRKDC | |
| Hydrochloric Acid SCHEMBL3493933 | 0.86 | CA1 (0.42) | KIF11ATMPIK3C3ATRPRKDC | |
| SCHEMBL3494487 | 0.82 | CA1 (0.42) | KIF11ATMPIK3C3PIM1KMO | |
| SCHEMBL3494809 | 0.82 | HCRTR1 (0.43) | KIF11ATM | |
| SCHEMBL5140406 | 0.78 | CPT1A (0.38) | ATRPIM1KMO | |
| SCHEMBL3495628 | 0.78 | CPT1A (0.38) | ATRPIM1KMO | |
| SCHEMBL3491780 | 0.78 | KMO (0.52) | ATRPRKDCPIM1KMO | |
| SCHEMBL5134025 | 0.76 | CA1 (0.44) | KIF11ATMKMO | |
| SCHEMBL3494697 | 0.76 | CA1 (0.44) | KIF11ATMKMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100121048-A1 | Cyclic Amine Compound and Use Thereof for the Prophylaxis or Treatment of Hypertension | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-13 | — | — | US | disclosed |
| US-20100121048-A1 | Cyclic Amine Compound and Use Thereof for the Prophylaxis or Treatment of Hypertension | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100121048-A1 | Cyclic Amine Compound and Use Thereof for the Prophylaxis or Treatment of Hypertension | REN, AGTR1, AGTR2 | KIF11 4471/4885ATM 2412/4885PIK3C3 3664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.